NewsRoom Articles - Page 39 of 144 - PsychedelicNewsWire (PNW)

MondaySep 12, 2022 1:54 pm

How Psychedelic Legalization, Decriminalization and Medicalization Differ

Over the past couple of years, there has been a significant resurgence in psychedelic interest among the mainstream and scientific communities. The media has shared endless stories of people who benefited greatly from psychedelic experiences as more scientists have published papers outlining the potential mental health benefits of pairing psychedelics with psychotherapy. Still, psychedelics remain illegal in most of the country, with only a few cities passing measures to decriminalize psilocybin, the psychoactive agent in magic mushrooms and, in limited cases, other psychedelics. With activists across the country fighting to get psychedelics removed from the Controlled Substances Act, the words…

FridaySep 09, 2022 1:12 pm

Canadian Minister Meets Members of Oregon Psilocybin Advisory Board

It has recently come to light that last month, the minister of mental health and addictions in Canada, Carolyn Bennett, met with Oregon’s Psilocybin Advisory Board. This board is responsible for the formulation of rules that will govern the legal use of psilocybin in the state of Oregon. Voters in Oregon voted to decriminalize all drugs in November 2020, as well as establish psilocybin healing centers where individuals aged 18 and above could legally receive psilocybin-assisted therapy. It is expected that these centers will be opened in 2023. Many hope that this surprising move by Bennett signifies easing of restrictions…

ThursdaySep 08, 2022 12:42 pm

New Research Finds Link Between Psychedelic-Induced Mystical Experiences and EcoFriendly Behavior

For the longest time, psychedelics have been stereotyped in popular media as “tree hugging” hippies with a long-drug particular devotion to psychedelic music and drugs. While this stereotype was certainly based on untruths, recent research has revealed that psychedelic users are more likely to display eco-friendly behavior. A new study, whose findings were reported in the “Journal of Humanistic Psychology,” has found that people who went through a mystical experience after using psychedelics are more likely to act in ways that conserve or protect the environment. Hallucinogenic drugs have long been famous for their effects on consciousness, with recent research…

WednesdaySep 07, 2022 11:48 am

Study Finds That LSD Temporarily Reduces Binge Drinking in Rodents

Alcoholism is a chronic illness that affects millions of individuals globally. Despite the presence of a range of effective therapies, not much is known about this problem, which is characterized by uncontrolled drinking. Prior studies suggest that when psychedelics are administered in conjunction with psychotherapy, they may effectively help to manage addiction. Despite these promising findings, minimal studies have looked into LSD’s influence on reward-linked behaviors in mice models. Mice models are often used to study alcoholism as they afford scientists insights into the behavioral and neurological changes that occur with the chronic use of alcohol. Now a new study…

TuesdaySep 06, 2022 11:55 am

Psychedelics, Near-Death Experiences Both Reduce Fear of Dying

A new study has found that psychedelics reduce depression and anxiety in patients with life-threatening illnesses, which in turn lessens their fear of dying and death. The study, which involved researchers from Johns Hopkins Medicine surveying 3,192 individuals, reported its findings in the “PLOS ONE” journal. For their study, the researchers administered an online survey to these participants from December 2015 to April 2018. The researchers divided the study subjects into groups based on those who had had psychedelic experiences brought on by psychedelics and those who had undergone a nondrug-linked near-death experience. The majority of the subjects had undergone…

FridaySep 02, 2022 11:07 am

Important Factors to Consider When Designing Psychedelic Clinical Trial Protocols

Companies have been investing big in psychedelic research in recent years, pouring some $60 million into psychedelic companies in 2018 and 2019. With the massive surge in interest in psychedelics among the mainstream and scientific communities, this investment is expected to balloon to more than $2 billion globally. But for the Food and Drug Administration to approve psychedelic-assisted therapies, researchers will have to prove via a series of clinical trials that the substances are effective and safe for human use. Given the unique mind-altering effects associated with hallucinogenic drugs such as psilocybin, ketamine, and MDMA, developers will have to approach…

ThursdaySep 01, 2022 11:26 am

Study Shows Psilocybin Helps Alcoholics Reduce Drinking

New research has found that psilocybin may help individuals with alcohol use disorders decrease their drinking. Figures show that roughly 20 million individuals in America struggle with substance use disorders. Currently, only a trio of drugs have been approved by the FDA for the treatment of this disorder. However, side effects such as nausea and vomiting are impeding adherence to those approved treatments. Earlier studies have shown that psilocybin possesses the potential to treat various addiction disorders, including opioid use disorder, alcohol use disorder and smoking. Psilocybin works by reshaping the neural networks in the brain associated with habits related…

WednesdayAug 31, 2022 1:33 pm

Researchers Push DEA to Rescind Psychedelic Restriction Plan

In April, the DEA announced its intent to place certain hallucinogens in Schedule I, which would make it harder for researchers to conduct studies investigating the therapeutic potential of those substances. This is in addition to criminalizing said substances. However, after scientists from Emory University and Panacea Plant Sciences challenged this action, the agency decided to withdraw the proposal altogether. In a recently released notice, the agency stated that it would rescind the ban on DOC (2,5-dimethoxy-4-chloroamphetamine) and DOI (2,5-dimethoxy-4-iodoamphetamine) and would instead publish a new proposed rule. The DEA’s justification for the original ban wasn’t backed by sufficient evidence…

WednesdayAug 31, 2022 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction with the psychedelic compound psilocybin. This news aligns with initiatives of Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, which has a drug in development, CYB003, for the treatment of alcohol…

TuesdayAug 30, 2022 12:36 pm

Psychedelics Company Raises More than $10M in Seed Funding to Advance Ketamine Therapy

Freedom Biosciences is a leading biotechnology platform focused on developing next-generation psychedelic therapies. The company was founded in April 2021 by Dina Burkitbayeva and Dr. John Krystal. Burkitbayeva is also the cofounder of PsyMed Ventures while Krystal is the psychiatry department chair at Yale University. The company has raised $10.5 million in seed financing and focused on advancing a ketamine therapy for the treatment of major depressive disorder. Ketamine is a dissociative drug that is commonly used as an anesthetic, as well as a drug to manage acute pain. Recent studies have found that the drug may also be useful…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050